Bioequivalence Study of NPC-12 (Sirolimus) Granules and Tablets

NCT ID: NCT03765944

Last Updated: 2019-02-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-12-05
• Study Completion Date: 2018-12-29

Brief Summary

The purpose of this study is to evaluate the bioequivalece of NPC-12 granules in compare with NPC-12T tablets in Japanese healthy Adults

Conditions

Bioequivalence Study

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

NPC-12 granule

NPC-12 granules (1.0g: 2mg sirolimus)

Group Type: ACTIVE_COMPARATOR

sirolimus

Intervention Type: DRUG

SIngle administration under fasted condition

NPC-12T tablet

NPC-12T 2 tablets (2mg sirolimus)

Group Type: ACTIVE_COMPARATOR

sirolimus

Intervention Type: DRUG

SIngle administration under fasted condition

Interventions

sirolimus

SIngle administration under fasted condition

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Japanese healthy subjects aged 20 to 39 years of age

2. Subjects with BMI ≥ 18.5 kg/m2 and < 25.0 kg/m2

3. Subjects who are considered by the investigator as suitable for participation in the trial from lab test results at screening

4. Subjects who are considered by the investigator as suitable for participation in the trial from lab test results on the day before administration

5. Subjects who write informed consent

6. Subjects who are able to comply with the study requirements during the study period

Exclusion Criteria

1. Subjects who have a history of hypersensitivity to sirolimus or sirolimus derivative

2. Subjects who have a history of hypersensitivity or allergies to other drug

3. SUbjects who have an acute or chronic infectious diseases

4. Subjects who have a current or a history of disease which is considered inappropriate to be involved in the study, or who has any current disease to require treatments

5. Subjects who have diagnosed with alcoholism or a history of alcoholism

6. Subjects who have an abnormal findings (pneumonia, etc) from the result of chest CT at screening

7. Subjects who have been administered other investigational drug within 12 weeks before the initial administration

8. Subjects who have performed blood collection or donation as follows

• Collected or donated 200 ml or more whole blood within 4 weeks before the initial administration
• Male subject; collected or donated more than 400 mL whole blood within 12 weeks before the initial administration
• Female subjects; collected or donated more than 400 mL whole blood within 16 weeks before the initial administration
• Collected or donated blood component within 2 weeks before the initial administration

9. Subjects who have positive results for HBs antigen, HBs antibody, HBc antibody, HCV antibody, HIV antigen/antibody, or syphilis

10. Subjects who received any non-prescription or prescription drug within 12 weeks before the initial administration

11. Subjects who are pregnant/lactating, or do not agree to contraception during the period from the screening until 8 weeks after the final administration due to planning to become pregnant

12. Subjects who cannot speak, read and write in Japanese

13. Subjects who are considered by the investigator as unsuitable for participation in the trial

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 39 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Nobelpharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Clinique Soigner

Matsudo, Chiba, Japan

Countries

Japan

Other Identifiers

NPC-12T-1

Identifier Type: -

Identifier Source: org_study_id